← Back to Clinical Trials
Recruiting NCT06260410
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
Trial Parameters
Condition Prostate Cancer Metastatic
Sponsor Erasmus Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex MALE
Min Age 18 Years
Max Age N/A
Start Date 2024-02-20
Completion 2027-02-01
Interventions
Blood draw for ctDNA and circulating tumor cell collection.
Brief Summary
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Eligibility Criteria
Inclusion Criteria: * Participants should be at least 18 years old. * Participants should be able to understand the written information and be able to provide informed consent. * Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care. Exclusion Criteria: None applicable
Related Trials
NCT06496581
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Re
View Trial →
NCT06260410
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characterist
View Trial →
NCT04086290
National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
View Trial →